Regulatory status brief
Retatrutide Availability and Investigational Status
A clear account of where retatrutide stands in the approval process — and what has to happen before it becomes an available medicine.
Where retatrutide stands right now
Retatrutide is not available as an approved medicine anywhere in the world. It is an investigational compound — meaning it is being studied in clinical trials but has not yet received regulatory approval from the FDA, the European Medicines Agency, or any equivalent body. The compound is available only to participants enrolled in sponsored clinical trials. Retatrutide availability as a prescription drug depends on Phase 3 trial success, regulatory submission, and approval — a process that has not yet begun. Any seller claiming to offer retatrutide as a prescription product or approved medication is making a false claim. Gray-market research-labeled material is a different category: unregulated, unverified, and outside any approval framework.
The clinical-trial timeline
Retatrutide's development follows the standard clinical-trial arc for a new drug, which has four phases before a drug reaches the market.
Phase 1 (2019–2022) — completed: The first-in-human Phase 1 study (NCT04143802) established safety, tolerability, and pharmacokinetics in healthy participants [11]. A Phase 1b multiple-ascending-dose trial in adults with type 2 diabetes confirmed a plasma half-life of approximately six days and generated the first weight-loss signal: −8.96 kg placebo-adjusted at the highest dose over 12 weeks [4]. These studies cleared the compound to enter larger trials.
Phase 2 (2022–2023) — completed: Phase 2 trials in obesity [1] and type 2 diabetes [2] confirmed the triple-agonist hypothesis at scale. Mean body-weight reduction of −24.2 percent at 48 weeks in the obesity trial [1] and −16.94 percent at 36 weeks in the diabetes trial [2], combined with HbA1c reductions of −2.02 percent [2], provided the efficacy basis for proceeding to Phase 3. A Phase 2 substudy also confirmed significant liver-fat reductions in MASLD [5].
Phase 3 (2023–ongoing) — the current stage: TRIUMPH-1 (NCT05929066) is the pivotal Phase 3 obesity trial [7]. TRIUMPH-3 (NCT05882045) adds an obesity-plus-cardiovascular-disease cohort [8]. A cardiovascular and kidney outcomes trial (NCT06383390) evaluates long-term organ safety [9]. A head-to-head trial versus tirzepatide (NCT06662383) adds the direct comparison evidence [10]. Phase 3 trials typically enroll thousands of participants across multiple countries and take 18–36 months to complete; results from the TRIUMPH program have not been published as of mid-2026.
After Phase 3: Eli Lilly would need to compile all trial data, submit a New Drug Application (NDA) to the FDA, and await a decision (typically 6–12 months for a standard review, potentially faster under Priority Review if granted). Retatrutide holds Fast Track designation, which facilitates early FDA engagement and may shorten some review timelines, but does not guarantee approval or a specific date.
When will retatrutide be available
No approval date has been announced. The public record as of mid-2026 places retatrutide in active Phase 3 recruitment and follow-up. Forecasting an approval date from current trial status is speculative — trial outcomes could differ from Phase 2, safety signals could emerge in larger populations, or additional follow-up could be required. Industry analysts have cited 2026–2027 as a plausible regulatory submission window if Phase 3 data are clean, but Eli Lilly has made no official commitment. This site will not speculate on timelines beyond what the published record and active trial listings support.
What clinical-trial enrollment means for access
The only legitimate current path to retatrutide is enrollment in one of the active TRIUMPH trials. Participants meeting inclusion criteria — BMI thresholds, absence of certain comorbidities, geographic proximity to a trial site — can receive the compound under supervised, monitored conditions at no cost, as part of the trial protocol. The ClinicalTrials.gov listings for NCT05929066 [7] and NCT05882045 [8] provide eligibility criteria, site locations, and contact information for the principal investigators.
This site is not affiliated with any trial site, Eli Lilly, or any clinical organization. We cannot facilitate enrollment. We document the published record; for enrollment inquiry, ClinicalTrials.gov is the authoritative resource.
The gray-market reality
Research-labeled retatrutide is sold through online vendors as a research compound. This material occupies a legally and scientifically fraught position. It is not an approved drug; it cannot be prescribed; it has no verified identity, purity, or sterility standard. The FDA issued over fifty warning letters to vendors in 2025 for distributing retatrutide in violation of the Federal FD&C Act. Independent analyses of similar gray-market peptides have documented truncated sequences, racemized amino acids, and cases of entirely different compounds sold under the correct label. Injection-site contamination from unsterile preparations carries infection risk.
This site does not link to vendors, does not evaluate vendor quality, and does not assist in procurement. The caution is grounded in the documented regulatory and analytical record, not in a generalized objection to research use.